Related Experiment Videos
Familial hypertrophic cardiomyopathy: diagnostic and therapeutic implications of recent genetic studies
1Section of Cardiology, Baylor College of Medicine, Houston, TX 77030, USA.
Insights
Familial hypertrophic cardiomyopathy (HCM) is the first primary cardiomyopathy studied using molecular genetics. Identifying four sarcomeric protein genes advances understanding of HCM
Area of Science:
- Cardiovascular Genetics
- Molecular Medicine
- Genetic Cardiology
Background:
- Familial hypertrophic cardiomyopathy (HCM) is a primary cardiomyopathy.
- Modern molecular genetics has begun to unravel the genetic basis of HCM.
Purpose of the Study:
- To review the progress in understanding the molecular genetics of HCM.
- To highlight the identification of genes responsible for HCM.
- To discuss the implications for diagnosis and therapy.
Main Methods:
- Review of recent molecular genetics studies on HCM.
- Analysis of identified genes coding for sarcomeric structural proteins.
- Genotype-phenotype correlation studies.
Main Results:
- Four genes responsible for familial hypertrophic cardiomyopathy have been identified.
- These genes encode sarcomeric structural proteins.
- Structure-function and genotype-phenotype studies illuminate the molecular basis of HCM.
Conclusions:
- Molecular genetics has significantly advanced the understanding of HCM.
- Future applications of molecular genetic tools promise improved diagnosis and risk stratification for HCM.
- This knowledge may lead to more targeted and definitive therapies for HCM.
Abstract:
Familial hypertrophic cardiomyopathy is the first primary cardiomyopathy to have yielded to the techniques of modern molecular genetics. In the past few years, four genes responsible for this disease have been identified, all of which code for sarcomeric structural proteins. In addition, structure-function analysis and genotype-phenotype correlation studies have shed significant light on the molecular basis of this disease. It is hoped that within the next few years the application of molecular genetic tools will not only facilitate the diagnosis of hypertrophic cardiomyopathy but will also provide prognostic and therapeutic stratification for more definitive therapy.